Lenalidomide safe as single therapy for elderly CLL patients

December 08, 2008

Drug shows activity against chronic lymphocytic leukemia in clinical trial

SAN FRANCISCO ― The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

"Lenalidomide has a favorable toxicity profile and shows signs of activity against CLL in our phase II clinical trial to date," said study presenter Alessandra Ferrajoli, M.D., associate professor in M. D. Anderson's Department of Leukemia.

Patients start on a 5 mg dose of the drug in pill form and the dose escalates over time in 5 mg increments to a maximum of 25 mg. The median age of participants is 72. Chemo-immunotherapy therapy combinations that are effective in younger patients with CLL tend to be associated with a high rate of complications in patients older than 70, Ferrajoli said.

Of 43 patients enrolled in the study, 35 were evaluable because they had been treated for at least three months. Nineteen of these (54 percent) achieved a partial response, where the disease is diminished, 14 patients (40 percent) had stable disease and continue on therapy, and two had their CLL progress.

Lenalidomide also rapidly reduced the number of circulating lymphocytes - the hallmark of the disease - in the patients' blood. Ferrajoli said 47 percent achieved a blood complete response and 38 percent had at least a partial response.

Patients on the trial for at least two months were evaluated for the drug's potential side effects. Of those 39 patients, 10 (26 percent) had decreased bone marrow activity resulting in a decrease in the number of either white blood cells called neutrophils or of platelets. Three patients had infections, two had fever and one had pneumonia.

All patients registered in the study remain alive with 37 of the 43 continuing on treatment. Ferrajoli said the trial will include up to 60 patients.

Lenalidomide, a drug developed by Celgene Corp. known commercially as Revlimid®, attacks both malignant cells and the cellular environment that nurtures them. The U.S. Food and Drug Administration has approved the drug for treatment of multiple myeloma and some forms of myelodysplastic syndrome.

University of Texas M. D. Anderson Cancer Center

---

---

	Thalidomide analog effective against B-CLL: lenalidomide had a 57.7% overall response rate in patients with relapsed and refractory ... An article from: Internal Medicine News by Bruce Wilson (Author) This digital document is an article from Internal Medicine News, published by Thomson Gale on January 15, 2007. The length of the article is 606 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Thalidomide analog effective against B-CLL: lenalidomide had a 57.7% overall response rate in patients with relapsed and refractory CLL.(Hematology)(B-cell chronic leukocytic leukemia) Author: Bruce Wilson Publication: Internal Medicine News (Magazine/Journal) Date: January 15, 2007 Publisher: Thomson Gale Volume: 40 Issue: 2 Page: 25(1) Distributed by Thomson...
	Lenalidomide: Webster's Timeline History, 2004 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Lenalidomide," including when used in literature (e.g. all authors that might have Lenalidomide in their name). As such, this book represents the largest compilation of timeline events associated with Lenalidomide when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social...
	Evaluation of lenalidomide (Revlimid[R]) to treat subjects with Cutaneous lupus erythematosus (CLE).(CONNECTIVE TISSUE DISORDERS)(Report): An article from: Journal of Drugs in Dermatology by Unavailable (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on December 1, 2009. The length of the article is 329 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Evaluation of lenalidomide (Revlimid[R]) to treat subjects with Cutaneous lupus erythematosus (CLE).(CONNECTIVE TISSUE DISORDERS)(Report) Author: Unavailable Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: December 1, 2009 Publisher: Journal of Drugs in Dermatology, Inc. Volume: 8 Issue: 12 Page: 1154(1) Article Type: Report Distributed...
	Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.(Case study): An article from: Journal of Drugs in Dermatology by Sirunya Silapunt (Author), Susan Y. Chon (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on March 1, 2010. The length of the article is 2136 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide.(Case study) Author: Sirunya Silapunt Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: March 1, 2010 Publisher: Journal of Drugs in Dermatology, Inc. Volume: 9 Issue: 3 Page: 273(4) Article Type: Case study Distributed by Gale, a part of Cengage...
	Lenalidomide in treating patients with AIDS-related Kaposi sarcoma.(KAPOSI'S SARCOMA): An article from: Journal of Drugs in Dermatology by Unavailable (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on February 1, 2011. The length of the article is 405 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Lenalidomide in treating patients with AIDS-related Kaposi sarcoma.(KAPOSI'S SARCOMA) Author: Unavailable Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: February 1, 2011 Publisher: Journal of Drugs in Dermatology, Inc. Volume: 10 Issue: 2 Page: 210(2) Distributed by Gale, a part of Cengage...
	Myeloma Therapy: Pursuing the Plasma Cell (Contemporary Hematology) by Sagar Lonial (Editor) Therapeutic options for patients with myeloma have radically changed over the past ten years. Beginning with the advances in therapy resulting from the use of high dose therapy and autologous bone marrow or stem cell transplant, we have more than doubled the median survival for patients as a whole, and have now a wealth of different biology based treatment approaches for our patients in all disease stages. The purpose of this book is to update the various treatment options for patients with myeloma, as well as to focus on the emerging and speculative aspects of myeloma therapy. This will require review of basic mechanisms of disease as well as further discussions on how these mechanisms can best be targeted. While there will be text covering most areas of myeloma therapy, the prime focus...
	Contemporary Management of Multiple Myeloma by Ravi, M.D. Vij (Author), Shaji K., M.D. Kumar (Foreword) Extensive discussion of the science of multiple myeloma, including the epidemiology, pathophysiology diagnosis, new diagnostic and prognostic criteria and various treatment options.
	Medifocus Guidebook on: Myelodysplastic Syndromes by Inc. Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Myelodysplastic Syndromes is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Myelodysplastic Syndromes, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Myelodysplastic Syndromes, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...
	Immunomodulating Drugs for the Treatment of Cancer by Asher A.A. Chanan-Khan (Author) Immunomodulatory (IMiDs) drugs are a new class of anticancer agents that has made a tremendous impact on the treatment of patients with various malignant diseases, including blood cancers and several cancers of the solid organs. Their popularity in prescribing is based on several important characteristics including: (1) oral bioavailability, (2) non-chemotherapeutic, (3) extremely well-tolerated in all age groups, (4) ability to activate patient's own immune response against cancer, (5) ease of combination with other agents such as chemotherapy resulting in higher responses as well as (6) variability of anticancer activity and a number of cancers. While there is a lot of literature published on these agents, there is no textbook that provides a comprehensive resource for clinicians and...
	Medifocus Guidebook on: Multiple Myeloma by Inc. Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Multiple Myeloma is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Multiple Myeloma, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Multiple Myeloma, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support...